Boston Scientific, MDMA call for more transparency, oversight of Medicare Advantage plans

Privately offered Medicare Advantage plans “do not often provide a clear reason for the denial of coverage, and rarely offer any visibility into the evidence and methodology,” trade group MDMA and Boston Scientific said.